Pharma Capital

Futura Medical pushing ahead with further CSD500 condom launches

James Barder, chief executive of Futura Medical plc. (LON:FUM) tells Proactive's Andrew Scott they've had a very productive six months as their breakthrough erectile dysfunction gel moves closer to its phase III study.

A mid-stage trial last September showed that MED2002 gets to work quicker than its competitors and has a favourable safety profile.

Futura also has its CSD500 erectogenic condom which was launched in Saudi Arabia at the beginning of the year.

They were dealt a blow by one its licensing partners, Church & Dwight Co Inc (NYSE:CHD), in August after it terminated its licensing agreement for CSD500 following a strange of strategy.

 

View full FUM profile

Futura Medical plc. Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.